News
GHRS
11.03
-1.43%
-0.16
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 2d ago
Weekly Report: what happened at GHRS last week (0408-0412)?
Weekly Report · 5d ago
Weekly Report: what happened at GHRS last week (0401-0405)?
Weekly Report · 04/08 10:22
Weekly Report: what happened at GHRS last week (0325-0329)?
Weekly Report · 04/01 10:21
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
Weekly Report: what happened at GHRS last week (0318-0322)?
Weekly Report · 03/25 10:23
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.
Benzinga · 03/20 18:49
Weekly Report: what happened at GHRS last week (0311-0315)?
Weekly Report · 03/18 10:22
Weekly Report: what happened at GHRS last week (0304-0308)?
Weekly Report · 03/11 10:20
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
NASDAQ · 03/05 14:55
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety Disorder. The medical psychedelics field is at a pivotal juncture. Clinical trial results show potential benefits for psilocybin therapy's potential for treatment of generalized anxiety disorder. Beckley Academy has published the first open-source learning framework to advance psychedelic-assisted therapy training standards. Enveric Biosciences has signed deals to license three types of drug compounds.
Benzinga · 03/04 18:48
GH Research Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 03/04 18:18
HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target
Benzinga · 03/04 18:08
Buy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property Advances
TipRanks · 03/04 16:36
Weekly Report: what happened at GHRS last week (0226-0301)?
Weekly Report · 03/04 10:22
GH Research Price Target Cut to $39.00/Share From $50.00 by JMP Securities
Dow Jones · 03/01 17:01
GH Research Is Maintained at Market Outperform by JMP Securities
Dow Jones · 03/01 17:01
JMP Securities Maintains Market Outperform on GH Research, Lowers Price Target to $39
Benzinga · 03/01 16:52
Oregon House passes bill to end hard drug decriminalization
New Zealand this week reversed a ban on tobacco sales to younger generations. Thailand just announced that it would ban the use of recreational cannabis by the end of this year. Oregon is getting second thoughts on decriminalizing hard drugs. The first U.S. State to decriminalize hard drugs has declared a fentanyl state of emergency.
Seeking Alpha · 03/01 11:42
Buy Rating Justified by GH Research’s Promising Clinical Trials and Strong Financial Health
TipRanks · 03/01 06:36
More
Webull provides a variety of real-time GHRS stock news. You can receive the latest news about Gh Research Plc through multiple platforms. This information may help you make smarter investment decisions.
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.